{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:11:21Z","timestamp":1779189081564,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002243"],"award-info":[{"award-number":["UL1 TR002243"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"crossref","award":["R35HL144980"],"award-info":[{"award-number":["R35HL144980"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001674","name":"Leducq Foundation","doi-asserted-by":"crossref","award":["18CVD05"],"award-info":[{"award-number":["18CVD05"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001674","name":"Leducq Foundation","doi-asserted-by":"crossref","award":["K23 HL127704"],"award-info":[{"award-number":["K23 HL127704"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by exercise-induced ventricular arrhythmias, sudden death, and sinus bradycardia. Elevating supraventricular rates with pacing or atropine protects against catecholaminergic ventricular arrhythmias in a CPVT mouse model. We tested the hypothesis that increasing sinus heart rate (HR) with atropine prevents exercise-induced ventricular arrhythmias in CPVT patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We performed a prospective open-label trial of atropine prior to exercise in CPVT patients (clinicaltrials.gov NCT02927223). Subjects performed a baseline standard Bruce treadmill test on their usual medical regimen. After a 2-h recovery period, subjects performed a second exercise test after parasympathetic block with atropine (0.04\u2009mg\/kg intravenous). The primary outcome measure was the total number of ventricular ectopic beats during exercise. All six subjects (5 men, 22\u201357\u2009years old) completed the study with no adverse events. Atropine increased resting sinus rate from median 52\u2009b.p.m. (range 52\u201364) to 98\u2009b.p.m. (84\u2013119), P\u2009=\u20090.02. Peak HRs (149\u2009b.p.m., range 136\u2013181 vs. 149\u2009b.p.m., range 127\u2013182, P\u2009=\u20090.46) and exercise duration (612\u2009s, range 544\u2013733 vs. 584\u2009s, range 543\u2013742, P\u2009=\u20090.22) were not statistically different. All subjects had ventricular ectopy during the baseline exercise test. Atropine pre-treatment significantly decreased the median number of ventricular ectopic beats from 46 (6\u2013192) to 0 (0\u201329), P\u2009=\u20090.026; ventricular ectopy was completely eliminated in 4\/6 subjects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Elevating sinus rates with atropine reduces or eliminates exercise-induced ventricular ectopy in patients with CPVT. Increasing supraventricular rates may represent a novel therapeutic strategy in CPVT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euaa029","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T20:09:36Z","timestamp":1579637376000},"page":"643-648","source":"Crossref","is-referenced-by-count":15,"title":["Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-9872","authenticated-orcid":false,"given":"Prince J","family":"Kannankeril","sequence":"first","affiliation":[{"name":"Thomas P. Graham Jr. Division of Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, 2220 Children\u2019s Way, Suite 5230, Nashville, TN 37232-9119, USA"},{"name":"Vanderbilt Center for Arrhythmia Research and Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Benjamin","family":"Shoemaker","sequence":"first","affiliation":[{"name":"Vanderbilt Center for Arrhythmia Research and Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA"},{"name":"Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn A","family":"Gayle","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darlene","family":"Fountain","sequence":"first","affiliation":[{"name":"Thomas P. Graham Jr. Division of Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, 2220 Children\u2019s Way, Suite 5230, Nashville, TN 37232-9119, USA"},{"name":"Vanderbilt Center for Arrhythmia Research and Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M","family":"Roden","sequence":"first","affiliation":[{"name":"Vanderbilt Center for Arrhythmia Research and Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA"},{"name":"Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"},{"name":"Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn C","family":"Knollmann","sequence":"first","affiliation":[{"name":"Vanderbilt Center for Arrhythmia Research and Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA"},{"name":"Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"2020040604554949800_euaa029-B1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.CIR.91.5.1512","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients","volume":"91","author":"Leenhardt","year":"1995","journal-title":"Circulation"},{"key":"2020040604554949800_euaa029-B2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jmg.2004.028993","article-title":"Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients","volume":"42","author":"Postma","year":"2005","journal-title":"J Med Genet"},{"key":"2020040604554949800_euaa029-B3","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1253\/circj.71.1606","article-title":"Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"71","author":"Sumitomo","year":"2007","journal-title":"Circ J"},{"key":"2020040604554949800_euaa029-B4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/01.CIR.103.2.196","article-title":"Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia","volume":"103","author":"Priori","year":"2001","journal-title":"Circulation"},{"key":"2020040604554949800_euaa029-B5","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/01.RES.0000038886.18992.6B","article-title":"Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia","volume":"91","author":"Postma","year":"2002","journal-title":"Circ Res"},{"key":"2020040604554949800_euaa029-B6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ajhg.2012.08.015","article-title":"Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death","volume":"91","author":"Nyegaard","year":"2012","journal-title":"Am J Hum Genet"},{"key":"2020040604554949800_euaa029-B7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1152\/jappl.1976.40.5.679","article-title":"Autonomic origin of heart rate fluctuations at the onset of muscular exercise","volume":"40","author":"Fagraeus","year":"1976","journal-title":"J Appl Physiol"},{"key":"2020040604554949800_euaa029-B8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1540-8167.2011.02188.x","article-title":"Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia","volume":"23","author":"Marjamaa","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2020040604554949800_euaa029-B9","doi-asserted-by":"crossref","first-page":"H2091","DOI":"10.1152\/ajpheart.00825.2001","article-title":"Parasympathetic effects on cardiac electrophysiology during exercise and recovery","volume":"282","author":"Kannankeril","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020040604554949800_euaa029-B10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1540-8167.2011.02138.x","article-title":"A classic electrocardiographic manifestation of catecholaminergic polymorphic ventricular tachycardia","volume":"23","author":"Richter","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2020040604554949800_euaa029-B11","first-page":"329097","article-title":"Postexertional supraventricular tachycardia in children with catecholaminergic polymorphic ventricular tachycardia","volume":"2012","author":"Else","year":"2012","journal-title":"Case Rep Cardiol"},{"key":"2020040604554949800_euaa029-B12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/CIRCRESAHA.111.300076","article-title":"Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients","volume":"112","author":"Faggioni","year":"2013","journal-title":"Circ Res"},{"key":"2020040604554949800_euaa029-B13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(67)90057-8","article-title":"Effects of atropine on heart-rate in healthy man","volume":"2","author":"Chamberlain","year":"1967","journal-title":"Lancet"},{"key":"2020040604554949800_euaa029-B14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2020040604554949800_euaa029-B15","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.hrthm.2015.03.033","article-title":"Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia","volume":"12","author":"Wang\u00fcemert","year":"2015","journal-title":"Heart Rhythm"},{"key":"2020040604554949800_euaa029-B16","doi-asserted-by":"crossref","first-page":"e0207100","DOI":"10.1371\/journal.pone.0207100","article-title":"Arrhythmia initiation in catecholaminergic polymorphic ventricular tachycardia type 1 depends on both heart rate and sympathetic stimulation","volume":"13","author":"Danielsen","year":"2018","journal-title":"PLoS One"},{"key":"2020040604554949800_euaa029-B17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.hrthm.2017.10.008","article-title":"Accentuated vagal antagonism paradoxically increases ryanodine receptor calcium leak in long-term exercised Calsequestrin2 knockout mice","volume":"15","author":"Ho","year":"2018","journal-title":"Heart Rhythm"},{"key":"2020040604554949800_euaa029-B18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/eurheartj\/eht452","article-title":"Calsequestrin 2 deletion causes sinoatrial node dysfunction and atrial arrhythmias associated with altered sarcoplasmic reticulum calcium cycling and degenerative fibrosis within the mouse atrial pacemaker complex","volume":"36","author":"Glukhov","year":"2015","journal-title":"Eur Heart J"},{"key":"2020040604554949800_euaa029-B19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tcm.2014.07.001","article-title":"Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target?","volume":"24","author":"Faggioni","year":"2014","journal-title":"Trends Cardiovasc Med"},{"key":"2020040604554949800_euaa029-B20","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/jce.14043","article-title":"Chronotropic incompetence as a risk predictor in children and young adults with catecholaminergic polymorphic ventricular tachycardia","volume":"30","author":"Franciosi","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2020040604554949800_euaa029-B21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hrthm.2015.09.029","article-title":"Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with \u03b21-selective \u03b2-blockers in patients with catecholaminergic polymorphic ventricular tachycardia","volume":"13","author":"Leren","year":"2016","journal-title":"Heart Rhythm"},{"key":"2020040604554949800_euaa029-B22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/europace\/eur277","article-title":"Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments","volume":"14","author":"van der Werf","year":"2012","journal-title":"Europace"},{"key":"2020040604554949800_euaa029-B23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrcardio.2012.93","article-title":"Inherited calcium channelopathies in the pathophysiology of arrhythmias","volume":"9","author":"Venetucci","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"2020040604554949800_euaa029-B24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1161\/01.CIR.96.1.260","article-title":"Effects of permanent pacemaker and oral theophylline in sick sinus syndrome","volume":"96","author":"Alboni","year":"1997","journal-title":"Circulation"},{"key":"2020040604554949800_euaa029-B25","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1378\/chest.99.6.1415","article-title":"The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants","volume":"99","author":"Bittar","year":"1991","journal-title":"Chest"},{"key":"2020040604554949800_euaa029-B26","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.hrthm.2014.04.030","article-title":"Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice","volume":"11","author":"Kurtzwald-Josefson","year":"2014","journal-title":"Heart Rhythm"},{"key":"2020040604554949800_euaa029-B27","doi-asserted-by":"crossref","first-page":"15222","DOI":"10.1038\/s41598-017-15632-x","article-title":"Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4","volume":"7","author":"Perera","year":"2017","journal-title":"Sci Rep"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/22\/4\/643\/32991379\/euaa029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/22\/4\/643\/32991379\/euaa029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T08:57:06Z","timestamp":1586163426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/22\/4\/643\/5753971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2,24]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euaa029","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,2,24]]}}}